<https://helda.helsinki.fi>

APOE epsilon 4, rs405509, and rs440446 promoter and
intron-1 polymorphisms and dementia risk in a cohort of elderly
Finns-Helsinki Birth Cohort Study

Rantalainen, Ville

2019-01

Rantalainen , V , Lahti , J , Kajantie , E , Tienari , P , Eriksson , J G & Raikkonen , K 2019 , '
APOE epsilon 4, rs405509, and rs440446 promoter and intron-1 polymorphisms and
dementia risk in a cohort of elderly Finns-Helsinki Birth Cohort Study ' , Neurobiology of
Aging , vol. 73 , ARTN 230.e5 . <https://doi.org/10.1016/j.neurobiolaging.2018.09.005>

<http://hdl.handle.net/10138/274092>

<https://doi.org/10.1016/j.neurobiolaging.2018.09.005>

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

APOE ε4, rs405509, and rs440446 promoter and intron-1 polymorphisms and dementia risk in a cohort of elderly Finns—Helsinki Birth Cohort Study

Ville Rantalainen^{a,*}, Jari Lahti^a, Eero Kajantie^b, Pentti Tienari^c, Johan G. Eriksson^d, Katri Raikkonen^e

^a Department of Psychology and Logopedics, University of Helsinki, Finland; Folkhälsan Research Centre, Helsinki, Finland

^b Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland; Hospital for Children and Adolescents, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland; PEDEGO Research Unit, MRC Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland

^c Department of Neurology, Helsinki University Central Hospital; Molecular Neurology, Research Programs Unit, Biomedicum, University of Helsinki, Helsinki, Finland

^d Department of General Practice, Primary Health Care, University of Helsinki, Helsinki University Hospital, Helsinki, Finland; Folkhälsan Research Center, Helsinki, Finland; National Institute for Health and Welfare, Helsinki, Finland

^e Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland

ARTICLE INFO

Article history:

Received 19 February 2018

Received in revised form 5 July 2018

Accepted 6 September 2018

Available online 12 September 2018

Keywords:

Dementia

Alzheimer's disease

APOE

Cohort studies

ABSTRACT

We tested if the ε4 major isoform of the APOE gene and rs405509 and rs440446 promoter and intron-1 polymorphisms predicted risk of any dementia or Alzheimer's disease with diagnoses derived from the Hospital Discharge and Causes of Death Registers in 1453 participants of the Helsinki Birth Cohort Study. We used Cox proportional hazard models adjusted for sex, year of birth, maximum lifetime occupational status and education, and diagnoses of stroke, coronary heart disease, mood disorders, and depressive symptoms. APOE ε4 predicted higher risk of any dementia (hazard ratios >3.68; 95% confidence interval [CI] 1.76, 7.70) across all statistical models, and when adjusted for rs405509 and rs440446. The number of minor alleles in rs405509 or rs440446 was not associated with dementia risk (hazard ratios <1.43; 95% CI 0.87, 2.36). As rs405509 or rs440446 has been associated with nonpathological cognitive aging in this and other cohorts independent of the APOE major isoforms, these findings lend credence that APOE locus may be linked with dementia risk and nonpathological cognitive aging via separate mechanisms.

© 2018 Elsevier Inc. All rights reserved.

1. Introduction

The ε4 major isoform of the APOE gene is a well-documented risk factor for Alzheimer's disease (AD) (Corder et al., 1993), dementia with Lewy bodies (Bras et al., 2014) as well as vascular dementia (Sun et al., 2015), and has also been found to be associated with cognitive functioning without dementia (Wisdom et al., 2011). In addition to the ε4 major isoform, the functional polymorphism rs405509 in the APOE gene promoter region has been found to be associated with AD risk (Lambert et al., 1998) as well as non-pathological cognitive aging (Rantalainen et al., 2016). However, research on this polymorphism has not been unanimous. Some studies have found higher AD risk associated with the major allele

(Beyer et al., 2005; Myllykangas et al., 2002) and others with the minor allele (Lambert et al., 1998; Nicodemus et al., 2004). Furthermore, some studies have reported risks differing with ethnicity (Lambert et al., 2002) or age of dementia onset (Beyer et al., 2005). It has also been unclear whether the promoter polymorphism's effects are truly independent of or due to linkage disequilibrium with APOE major isoforms (Jun et al., 2012; Roses et al., 2010).

It has been suggested that the APOE locus is associated with nonpathological cognitive aging and dementia risk via separate mechanisms (Deary et al., 2002). However, there have thus far been no studies to report associations of APOE major isoforms and rs405509 promoter polymorphisms with both outcomes in a single study population. We recently reported that while the APOE major isoforms were not associated with cognitive ability in elderly men from the Helsinki Birth Cohort Study (HBCS), the number of minor alleles in rs405509 and in another functional polymorphism, rs440446 in the APOE gene intron-1, predicted better preserved

* Corresponding author at: Department of Psychology and Logopedics, University of Helsinki, Finland; Folkhälsan Research Centre, Helsinki, Finland. Tel.: +358 504486475; fax: +358 919129521.

E-mail address: ville.rantalainen@helsinki.fi (V. Rantalainen).

cognitive ability independent of the *APOE* major isoforms (Rantalainen et al., 2016). Here we extend these analyses and study whether these genetic variants predict dementia risk in participants derived from this same study population.

2. Methods

2.1. Participants

The HBCS includes a random sample of 2003 participants. Of them, data on *APOE* major isoforms, rs405509, rs440446, and dementia diagnoses were available for 1453 participants (72.5%).

Compared with the rest of the cohort, the participants in the analytic sample were more likely to have attained maximum lifetime upper clerical occupation ($p < 0.001$) and tertiary education ($p < 0.001$).

2.2. Ethics statement

The HBCS has been approved by the Ethics Committee of the National Public Health Institute and the Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa.

2.3. Genotyping

Genotyping and linkage disequilibria between markers have been described (Rantalainen et al., 2016). In this sample, the biallelic sites that are used to determine *APOE* major isoforms (Arg112/Cys and Arg158/Cys) and rs405509 and rs440446 were at Hardy-Weinberg equilibrium (not shown).

2.4. Dementia diagnoses

Diagnoses of any organic dementias, given in inpatient (1969–2013) and outpatient (1998–2013) specialty care (codes 290.00–290.10 from International Classification of Diseases [ICD]-8, 290, 2912A, 2928C, 2941A, 3310A, and 3311A from ICD-9, and F00, F01, F03, F051, and G30 from ICD-10) and AD (codes 331.0 and 290.1 from ICD-9, and G30 and F00 from ICD-10) until the end of 2013 were derived from the Finnish Hospital Discharge and Causes of Death Registers.

2.5. Covariates and confounders

These included the participant's sex, year of birth extracted from hospital records, highest attained occupational status (manual worker, junior clerical, and senior clerical), and highest attained

level of education in adulthood (lower secondary or less, upper secondary, lower tertiary, and upper tertiary) recorded at 5-year intervals between 1970 and 2000 derived from Statistics Finland, and diagnoses of stroke (codes 430–434 and 436–437 from ICD-8 and -9, 438 from ICD-9, and I60–I69 from ICD-10) (Barker et al., 2005), coronary heart disease (codes 410–414 from ICD-8 and -9 and I21–I25 from ICD-10) (Osmond et al., 2007), and mood disorders (codes 296, 298.00, 3004, and 301.10 from ICD-8; 296, 3004A, and 3011D from ICD-9; and F30–F39 from ICD-10) until the end of 2013 derived from the Hospital Discharge Register, depressive symptoms reported using the Beck Depression Inventory (Beck et al., 1961) at the time of drawing blood for DNA extraction, and the first 3 multidimensional scaling components derived from genomewide data to account for population stratification.

2.6. Statistical methods

Cox Proportional Hazards models examined the associations between *APOE* $\epsilon 4$ ($\epsilon 4$ carriers vs. noncarriers as referent), and the number of minor alleles in rs405509 and in rs440446 and risk of any dementia and AD (no dementia as referent). The participants were followed up until their first hospitalization for any dementia, death, migration, or until December 31, 2013. We first examined the associations of *APOE* $\epsilon 4$, rs405509, and rs440446 with dementia risk in separate models and then entered rs405509 and rs440446 in the models with *APOE* $\epsilon 4$. We also tested the associations of rs405509 and rs440446 with dementia risk separately in $\epsilon 4$ carriers and $\epsilon 3/3$ homozygotes, which enables unambiguous haplotyping (see Myllykangas et al., 2002; Rantalainen et al., 2016; Strandberg et al., 2005; Viiri et al., 2008) as rs405509 and rs440446 are in linkage disequilibrium with the $\epsilon 2$ or $\epsilon 4$ major isoforms (Jun et al., 2012; Rantalainen et al., 2016; Roses et al., 2010). The analyses were adjusted first for sex, year of birth, and population stratification, and then for the other covariates.

3. Results

Sample characteristics according to *APOE* major isoforms are presented in [Supplementary Table 1](#).

APOE $\epsilon 4$ was associated with a higher risk of any dementia in all statistical models (hazard ratios [HRs] > 3.68 ; 95% confidence interval [CI] 1.76, 7.70) (Table 1, [Supplementary Fig. 1](#)). The number of minor alleles in rs405509 or rs440446 was not significantly associated with any dementia risk in any of the models (all HRs < 1.43 ; 95% CI 0.87, 2.36), and was not either associated with any dementia risk in *APOE* $\epsilon 3/3$ homozygotes (all HRs < 0.81 ; 95% CI 0.33, 1.99) or

Table 1
Risk of any dementia according to *APOE* $\epsilon 4$ and rs405509 and rs440446 polymorphisms

Genotype	Model 1 ^a		Model 2 ^b		Model 3 ^c		Model 4 ^d	
	HR (95% CI)	<i>p</i>	HR (95% CI)	<i>p</i>	HR (95% CI)	<i>p</i>	HR (95% CI)	<i>p</i>
<i>APOE</i> $\epsilon 4$ and number of rs405509 minor T alleles and rs440446 minor C alleles in separate models								
<i>APOE</i> $\epsilon 4$	3.70 (1.75, 7.64)	0.001	3.86 (1.84, 8.10)	<0.001	3.68 (1.76, 7.70)	0.001	3.83 (1.82, 8.04)	<0.001
rs405509T	1.40 (0.86, 2.29)	0.182	1.41 (0.86, 2.31)	0.172	1.41 (0.86, 2.32)	0.176	1.43 (0.87, 2.36)	0.158
rs440446C	0.76 (0.41, 1.42)	0.394	0.75 (0.40, 1.40)	0.363	0.76 (0.41, 1.43)	0.401	0.76 (0.40, 1.43)	0.387
<i>APOE</i> $\epsilon 4$ and number of rs405509 minor T alleles in the same model								
<i>APOE</i> $\epsilon 4$	3.77 (1.67, 8.52)	0.001	4.06 (1.77, 9.30)	0.001	3.83 (1.69, 8.71)	0.001	3.96 (1.74, 9.05)	0.001
rs405509T	0.95 (0.54, 1.68)	0.864	0.93 (0.53, 1.63)	0.789	0.94 (0.53, 1.67)	0.829	0.95 (0.54, 1.67)	0.850
<i>APOE</i> $\epsilon 4$ and number of rs440446 minor C alleles in the same model								
<i>APOE</i> $\epsilon 4$	3.14 (1.41, 6.96)	0.005	3.29 (1.48, 7.31)	0.003	3.14 (1.41, 6.97)	0.005	3.30 (1.48, 7.36)	0.004
rs440446C	1.00 (0.51, 1.94)	0.988	0.96 (0.49, 1.88)	0.909	1.00 (0.51, 1.96)	1.000	0.99 (0.50, 1.96)	0.980

Key: HR, hazard ratio; 95% CI, 95% confidence interval.

^a Model 1 adjusting for sex, year of birth, and population stratification.

^b Model 2 adjusting for sex, year of birth, maximum attained lifetime occupational status, and population stratification.

^c Model 3 adjusting for sex, year of birth, maximum attained lifetime educational status, and population stratification.

^d Model 4 adjusting for sex, year of birth, maximum attained lifetime occupational status, population stratification, diagnoses of stroke, coronary heart disease or any mood disorder, and BDI score.

APOE $\epsilon 4$ carriers (all HRs < 1.09; 95% CI 0.39, 3.06) (for any dementia, $n = 11$ in *APOE* $\epsilon 3/3$ homozygotes and $n = 20$ in *APOE* $\epsilon 4$ carriers). When we entered *APOE* $\epsilon 4$ simultaneously with rs405509 and rs440446 in respective models, *APOE* $\epsilon 4$ remained a significant predictor of dementia risk (Table 1). In analyses with risk of AD, the results were similar (Supplementary Table 2; data of stratified analyses in *APOE* $\epsilon 3/3$ homozygotes and *APOE* $\epsilon 4$ carriers not shown, $n = 7$ and $n = 16$ with AD, respectively).

4. Discussion

Our result is in accordance with the suggestion that the *APOE* gene may be associated with dementia risk and nonpathological cognitive aging via separate mechanisms (Deary et al., 2002). Together with the finding that rs405509 and rs440446, but not $\epsilon 4$, were associated with nonpathological cognitive aging (Rantalainen et al., 2016), the result suggests that the *APOE* locus may be linked with dementia risk via an isoform-dependent mechanism and with nonpathological cognitive aging via an isoform-independent mechanism in this cohort. However, further studies are needed to determine if a similar pattern of associations is found in other samples derived from 1 study population.

Our results replicate the expected association between *APOE* $\epsilon 4$ and a higher risk of any dementia and AD (Corder et al., 1993; Sun et al., 2015). These associations were independent of participant's sex, year of birth, highest attained lifetime occupation and level of education, diagnoses of stroke, cardiovascular disease or any mood disorder, and depressive symptoms, as well as the number of minor alleles in rs405509 or rs440446. However, the number of minor alleles in rs405509 or rs440446 was not associated with risk of dementia. This latter finding is in disagreement with some (Beyer et al., 2005; Lambert et al., 1998; Myllykangas et al., 2002) but not all (Jun et al., 2012) previous studies. Our study is unable to confirm or refute the possibility that these discrepancies may be due to ethnicity (Lambert et al., 2002) or age of dementia onset (Beyer et al., 2005).

Strengths of this study include availability of data on dementia diagnoses from national registers in a well-characterized lifespan longitudinal cohort followed up to 69–79 years of age. Our study has the major limitation of a small sample size and a small number of dementia or AD cases. Our findings should therefore be considered preliminary and await replication in larger samples with lifespan data on nonpathological cognitive aging and dementia. However, dementia prevalence (2.1%) in our sample is similar to Finnish nation-level estimates (2.4%) (Prince et al., 2015), and the relative contributions of *APOE* $\epsilon 4$, rs405509, and rs440446 to dementia risk are less likely to change as our cohort ages. As the effect of *APOE* $\epsilon 4$ on dementia risk diminishes after age 70 years (Farrer et al., 1997), and as rs405509 and rs440446 are in linkage disequilibrium with $\epsilon 4$ (Jun et al., 2012; Rantalainen et al., 2016; Roses et al., 2010), the proportion of the rs405509T and rs440446G alleles, that are more common in $\epsilon 4$ carriers with dementia, will likely diminish according to age as well, and an increasing proportion of carriers of these alleles among participants who receive a dementia diagnosis will likely be $\epsilon 4$ noncarriers. As the cohort was born in 1930s and 1940s, generalizations to more recent cohorts cannot be made. This however remains an unavoidable limitation of studying aging-related diseases in today's elderly. Finally, residual confounding cannot be entirely excluded.

Disclosure statement

The authors have no actual or potential conflicts of interest.

Acknowledgements

The Helsinki Birth Cohort Study has been funded by The Academy of Finland (grant numbers 269925, 311617, 127437, 129306, 130326, 134791, and 263924), the Finnish Diabetes Research society, Folkhälsan Research Foundation, Novo Nordisk Foundation, Finska Läkaresällskapet, Signe and Ane Gyllenberg Foundation, Sigrid Juselius Foundation, Foundation for Pediatric Research, University of Helsinki, Ministry of Education, Ahokas Foundation, Emil Aaltonen Foundation, Juho Vainio Foundation, Foundation for Cardiovascular Research, Helsinki University Hospital, and the European Commission within the 7th Framework Programme (DORIAN, grant agreement no. 278603), European Union Horizon 2020 programme (DYNAHEALTH grant no. 633595) and European Union Horizon 2020 programme (LifeCycle grant no. 733206) and European Union Horizon 2020 programme RECAP Research on Children and Adults Born Preterm grant no. 733280).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.neurobiolaging.2018.09.005>.

References

- Barker, D.J., Osmond, C., Forsén, T.J., Kajantie, E., Eriksson, J.G., 2005. Trajectories of growth among children who have coronary events as adults. *N. Engl. J. Med.* 353, 1802–1809.
- Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J., 1961. An inventory for measuring depression. *Arch. Gen. Psychiatry* 4, 561–571.
- Beyer, K., Lao, J.L., Latorre, P., Ariza, A., 2005. Age at onset an essential variable for the definition of genetic risk factors for sporadic Alzheimer's disease. *Ann. N. Y. Acad. Sci.* 1057, 260–278.
- Bras, J., Guerreiro, R., Darwent, L., Parkkinen, L., Ansorge, O., Escott-Price, V., Hernandez, D.G., Nalls, M.A., Clark, L.N., Honig, L.S., Marder, K., Van Der Flier, W.M., Lemstra, A., Scheltens, P., Rogeava, E., St George-Hyslop, P., Londos, E., Zetterberg, H., Ortega-Cubero, S., Pastor, P., Ferman, T.J., Graff-Radford, N.R., Ross, O.A., Barber, L., Braae, A., Brown, K., Morgan, K., Maetzler, W., Berg, D., Troakes, C., Al-Sarraj, S., Lashley, T., Compta, Y., Revesz, T., Lees, A., Cairns, N., Halliday, G.M., Mann, D., Pickering-Brown, S., Dickson, D.W., Singleton, A., Hardy, J., 2014. Genetic analysis implicates *APOE*, *SNCA* and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. *Hum. Mol. Genet.* 23, 6139–6146.
- Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., Pericak-Vance, M.A., 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261, 921–923.
- Deary, I.J., Whiteman, M.C., Pattie, A., Starr, J.M., Hayward, C., Wright, A.F., Carothers, A., Whalley, L.J., 2002. Cognitive change and the *APOE* $\epsilon 4$ allele. *Nature* 418, 932.
- Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Myers, R., Pericak-Vance, M.A., Risch, N., van Duijn, C.M., 1997. For the *APOE* and Alzheimer disease meta-analysis consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease A meta-analysis. *JAMA* 278, 1349–1356.
- Jun, G., Vardarajan, B.N., Buross, J., Yu, C.-E., Hawk, M.V., Dombroski, B.A., Crane, P.K., Larson, E.B., Mayeux, R., Haines, J.L., Lunetta, K.L., Pericak-Vance, M.A., Schellenberg, G.D., Farrer, L.A., 2012. Comprehensive search for Alzheimer disease susceptibility loci in the *APOE* region. *Arch. Neurol.* 69, 1270–1279.
- Lambert, J.-C., Berr, C., Pasquier, F., Delacourte, A., Frigard, B., Cottel, D., Pérez-Tur, J., Mouroux, V., Mohr, M., Cécylre, D., Galasko, D., Lendon, C., Poirier, J., Hardy, J., Mann, D., Amouyel, P., Chartier-Harlin, M.-C., 1998. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural *APOE* gene expression and risk of developing Alzheimer's disease. *Hum. Mol. Genet.* 7, 1511–1516.
- Lambert, J.-C., Araria-Goumide, L., Myllykangas, L., Ellis, C., Wang, J.C., Bullido, M.J., Harris, J.M., Artiga, M.J., Hernandez, D., Kwon, J.M., Frigard, B., Petersen, R.C., Cumming, A.M., Pasquier, F., Sastre, I., Tienari, P.J., Frank, A., Sulkava, R., Morris, J.C., St Clair, D., Mann, D.M., Wavrant-DeVrièze, F., Ezquerro-Trabalón, M., Amouyel, P., Hardy, J., Haltia, M., Valdivieso, F., Goate, A.M., Pérez-Tur, J., Lendon, C.L., Chartier-Harlin, M.C., 2002. Contribution of *APOE* promoter polymorphisms to Alzheimer's disease risk. *Neurology* 59, 59–66.
- Myllykangas, L., Polvikoski, T., Reunanen, K., Wavrant-De Vrièze, F., Ellis, C., Hernandez, D., Sulkava, R., Kontula, K., Verkkoniemi, A., Notkola, I.-L., Hardy, J., Pérez-Tur, J., Haltia, M.J., Tienari, P.J., 2002. ApoE $\epsilon 3$ -haplotype

- modulates Alzheimer beta-amyloid deposition in the brain. *Am. J. Med. Genet.* 114, 288–291.
- Nicodemus, K.K., Stenger, J.E., Schmechel, D.E., Welsh-Bohmer, K.A., Saunders, A.M., Roses, A.D., Gilbert, J.R., Vance, J.M., Haines, J.L., Pericak-Vance, M.A., Martin, E.R., 2004. Comprehensive association analysis of *APOE* regulatory region polymorphisms in Alzheimer disease. *Neurogenetics* 5, 201–208.
- Osmond, C., Kajantie, E., Forsén, T.J., Eriksson, J.G., Barker, D.J., 2007. Infant growth and stroke in adult life. The Helsinki birth cohort study. *Stroke* 38, 264–270.
- Prince, M., Wimo, A., Guerchet, M., Ali, G.-C., Wu, Y.-T., Prina, M., 2015. In: World Alzheimer report 2015: the global impact of dementia – an analysis of prevalence, incidence, cost and trends, 84. *Alzheimers Dis Int*, London.
- Rantalainen, V., Lahti, J., Henriksson, M., Kajantie, E., Tienari, P., Eriksson, J.G., Raikonen, K., 2016. *APOE* and aging-related cognitive aging in a longitudinal cohort of men. *Neurobiol. Aging* 44, 151–158.
- Roses, A., Lutz, M.W., Amrine-Madsen, H., Saunders, A.M., Crenshaw, D.G., Sundseth, S.S., Huentelman, M.J., Welsh-Bohmer, K.A., Reiman, E.M., 2010. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. *Pharmacogenomics J.* 10, 375–384.
- Strandberg, T.E., Pitkälä, K., Eerola, J., Tilvis, R., Tienari, P.J., 2005. Interaction of herpesviridae, *APOE* gene, and education in cognitive impairment. *Neurobiol. Aging* 26, 1001–1004.
- Sun, J.-H., Tan, L., Wang, H.-F., Tan, M.-S., Tan, L., Li, J.-Q., Xu, W., Zhu, X.-C., Jiang, T., Yu, J.-T., 2015. Genetics of vascular dementia: systematic review and meta-analysis. *J. Alzheimers Dis.* 46, 611–629.
- Viiri, L.E., Viiri, K.M., Ilveskoski, E., Huhtala, H., Mäki, M., Tienari, P.J., Perola, M., Lehtimäki, T., Karhunen, P.J., 2008. Interactions of functional apolipoprotein E gene promoter polymorphisms with smoking on aortic atherosclerosis. *Circ. Cardiovasc. Genet.* 1, 107–116.
- Wisdom, N.M., Callahan, J.L., Hawkins, K.A., 2011. The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. *Neurobiol. Aging* 32, 63–74.